Tissue Therapies Limited  

(Public, ASX:TIS)   Watch this stock  
Find more results for TIS
0.0000 (0.00%)
Feb 11 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range     -
52 week 0.03 - 0.25
Open     -
Vol / Avg. 0.00/141,132.00
Mkt cap 11.81M
P/E     -
Div/yield     -
EPS -0.05
Shares 302.88M
Beta     -
Inst. own     -
Jan 27, 2016
Interim 2016 Tissue Therapies Ltd Earnings Release
Jan 25, 2016
Tissue Therapies Ltd KPI Quarterly Report - December 2015
Dec 21, 2015
Tissue Therapies Ltd FDA Regulatory Progress Update Conference Call
Nov 25, 2015
Tissue Therapies Ltd Annual Shareholders Meeting

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -4590.39% -2132.07%
Operating margin -4577.86% -2113.22%
EBITD margin - -2097.89%
Return on average assets -192.26% -65.92%
Return on average equity -223.61% -74.33%
CDP Score - -


L 19 179 Turbot St
+61-7-33343900 (Phone)
+61-7-33343999 (Fax)

Website links


Tissue Therapies Limited is an Australia-based biomedical technology company which develops and manufactures proteins for healing wounds. The Company provides effective treatments for acute and chronic wound, including chronic skin ulcers and burns. The company also provides treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. VitroGro ECM, a product of Tissue Therapies, is a solution of synthetic protein that promotes healing and reduces pain in chronic wounds. The product is applied to the surface of a prepared wound and the liquid formulation allows the product to cover the irregular shape of the wound. Tissue Therapies Europe Limited a wholly owned subsidiary which is set up to provide administration support to Tissue Therapies Limited.

Officers and directors

Nigel Johnson Acting Chief Executive Officer
Zee Upton Chief Scientific Officer
Christian P. Behrenbruch Ph.D. Executive Director
Saskia Jo Company Secretary
Cherrell Hirst Non-Executive Director
Timothy Richard Hughes Non-Executive Director